West Pharmaceutical Services (WST) Research

Forward Estimates

EPS Estimates

Current Qtr

$2.08

$2.05$2.12

vs $1.84+13.1%

11 analysts

Next Qtr

$2.12

$2.08$2.17

vs $1.96+8.3%

11 analysts

Current Yr

$8.61

$8.47$8.82

vs $7.29+18.1%

15 analysts

Next Yr

$9.54

$9.07$10.28

vs $8.61+10.8%

15 analysts

Revenue Estimates

Current Qtr

$838.32M

$830.00M$849.70M

vs $766.50M+9.4%

10 analysts

Next Qtr

$814.67M

$804.80M$824.70M

vs $804.60M+1.3%

10 analysts

Current Yr

$3.33B

$3.30B$3.40B

vs $3.07B+8.4%

14 analysts

Next Yr

$3.54B

$3.45B$3.65B

vs $3.33B+6.2%

14 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for WST on EDGAR.

WST filing events and research context
Filed	Item	Context
Feb 17, 2026	business	West Pharmaceutical Services is a global leader in the design and manufacture of integrated containment and delivery systems for injectable drugs. The company operates through two primary segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment, which drives the company’s core value proposition, provides high-end elastomers, stoppers, seals, and advanced drug delivery devices such as self-injection systems. These products are engineered to ensure drug stability, mitigate glass-related breakage or incompatibility, and support the growing trend toward at-home patient care. This segment also offers value-added analytical lab services and regulatory support, positioning the company as a critical partner in the pharmaceutical supply chain. The Contract-Manufactured Products segment leverages specialized expertise in clean-room molding, ultrasonic welding, and high-speed automated assembly to produce complex devices for surgical, diagnostic, and ophthalmic applications. With over 56% of consolidated net sales generated outside the United States, the company maintains a significant international footprint across North America, Europe, and Asia. Key operational risks include exposure to foreign currency volatility and the complexities of managing multiple tax jurisdictions. The company’s strategic focus remains on high-quality manufacturing standards to meet the stringent requirements of global biologic and pharmaceutical customers.
Feb 17, 2026	mda	West Pharmaceutical Services (WST) maintains a dominant market position by providing proprietary containment and delivery systems for injectable medicines, primarily serving the high-growth biologics and pharmaceutical sectors. The company’s financial performance is anchored by its high-value products, including NovaPure, FluroTec, and Daikyo Crystal Zenith, which command premium pricing due to their specialized material science and contamination-control properties. Revenue growth is driven by the increasing complexity of injectable drug formulations and the global shift toward self-administration, which bolsters demand for the company’s proprietary delivery platforms. Operational efficiency remains a critical focus, with management prioritizing capital investments in global manufacturing capacity to mitigate supply chain volatility and meet stringent regulatory standards. Key risks include fluctuations in foreign currency exchange rates, potential disruptions in the global supply chain for raw materials, and the inherent regulatory hurdles associated with pharmaceutical manufacturing. Furthermore, the company faces competitive pressure from alternative packaging solutions and must navigate the cyclical nature of customer inventory levels, particularly following periods of pandemic-related demand surges. Sustained profitability depends on the company’s ability to leverage its technical expertise to secure long-term partnerships with major pharmaceutical developers while maintaining rigorous quality control across its international production footprint.
Feb 17, 2026	risk_factors	West Pharmaceutical Services faces several operational and macroeconomic risks that could impact its financial performance. The company’s reliance on global manufacturing exposes it to geopolitical volatility, including U.S. government tariffs and retaliatory trade restrictions in foreign jurisdictions. While the impact on 2025 results was not material, ongoing trade tensions remain a monitoring priority. The company’s financial results are sensitive to fluctuations in foreign currency exchange rates, as over 56% of net sales are generated outside the U.S. While West utilizes derivative instruments like forward exchange contracts and cross-currency swaps to hedge these exposures, significant currency volatility can still affect reported earnings. Additionally, the company faces commodity price risk, particularly regarding synthetic elastomers derived from petroleum. Although West employs long-term supply contracts and crude oil call options to mitigate these costs, sustained price volatility could pressure gross margins. Operational risks include the successful execution of restructuring programs, such as the January 2025 plan and the divestiture of the SmartDose® 3.5mL system to AbbVie. Furthermore, the company is currently defending against a securities class action lawsuit alleging violations of the Securities Exchange Act, which introduces legal uncertainty. Finally, West’s reliance on high-value product components and integrated systems requires continuous R&D investment to maintain competitive positioning.

Filed

Item

Context

Feb 17, 2026

business

West Pharmaceutical Services is a global leader in the design and manufacture of integrated containment and delivery systems for injectable drugs. The company operates through two primary segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment, which drives the company’s core value proposition, provides high-end elastomers, stoppers, seals, and advanced drug delivery devices such as self-injection systems. These products are engineered to ensure drug stability, mitigate glass-related breakage or incompatibility, and support the growing trend toward at-home patient care. This segment also offers value-added analytical lab services and regulatory support, positioning the company as a critical partner in the pharmaceutical supply chain. The Contract-Manufactured Products segment leverages specialized expertise in clean-room molding, ultrasonic welding, and high-speed automated assembly to produce complex devices for surgical, diagnostic, and ophthalmic applications. With over 56% of consolidated net sales generated outside the United States, the company maintains a significant international footprint across North America, Europe, and Asia. Key operational risks include exposure to foreign currency volatility and the complexities of managing multiple tax jurisdictions. The company’s strategic focus remains on high-quality manufacturing standards to meet the stringent requirements of global biologic and pharmaceutical customers.

Feb 17, 2026

mda

West Pharmaceutical Services (WST) maintains a dominant market position by providing proprietary containment and delivery systems for injectable medicines, primarily serving the high-growth biologics and pharmaceutical sectors. The company’s financial performance is anchored by its high-value products, including NovaPure, FluroTec, and Daikyo Crystal Zenith, which command premium pricing due to their specialized material science and contamination-control properties. Revenue growth is driven by the increasing complexity of injectable drug formulations and the global shift toward self-administration, which bolsters demand for the company’s proprietary delivery platforms. Operational efficiency remains a critical focus, with management prioritizing capital investments in global manufacturing capacity to mitigate supply chain volatility and meet stringent regulatory standards. Key risks include fluctuations in foreign currency exchange rates, potential disruptions in the global supply chain for raw materials, and the inherent regulatory hurdles associated with pharmaceutical manufacturing. Furthermore, the company faces competitive pressure from alternative packaging solutions and must navigate the cyclical nature of customer inventory levels, particularly following periods of pandemic-related demand surges. Sustained profitability depends on the company’s ability to leverage its technical expertise to secure long-term partnerships with major pharmaceutical developers while maintaining rigorous quality control across its international production footprint.

Feb 17, 2026

risk_factors

West Pharmaceutical Services faces several operational and macroeconomic risks that could impact its financial performance. The company’s reliance on global manufacturing exposes it to geopolitical volatility, including U.S. government tariffs and retaliatory trade restrictions in foreign jurisdictions. While the impact on 2025 results was not material, ongoing trade tensions remain a monitoring priority. The company’s financial results are sensitive to fluctuations in foreign currency exchange rates, as over 56% of net sales are generated outside the U.S. While West utilizes derivative instruments like forward exchange contracts and cross-currency swaps to hedge these exposures, significant currency volatility can still affect reported earnings. Additionally, the company faces commodity price risk, particularly regarding synthetic elastomers derived from petroleum. Although West employs long-term supply contracts and crude oil call options to mitigate these costs, sustained price volatility could pressure gross margins. Operational risks include the successful execution of restructuring programs, such as the January 2025 plan and the divestiture of the SmartDose® 3.5mL system to AbbVie. Furthermore, the company is currently defending against a securities class action lawsuit alleging violations of the Securities Exchange Act, which introduces legal uncertainty. Finally, West’s reliance on high-value product components and integrated systems requires continuous R&D investment to maintain competitive positioning.

Forward Estimates

WST filing events and research context

Keep researching WST

Related tickers

Related explainers

Forward Estimates